Il 23 inhibitor drugs

In addition to Janus kinase inhibitors (JAKi), four classes of biologic DMARDs (bDMARDs; interleukin [IL]-23 inhibitors [IL-23i], IL-12/23 inhibitors [IL-12/23i], tumor necrosis factor inhibitors [TNFi], and IL-17 inhibitors [IL-17i]) are currently approved for moderate to severe PsA treatment.

TNF-α and IL-12/IL-23 inhibitors remain the most reliable options for treating both conditions, while newer agents like IL-23 inhibitors hold

IL-12/IL-23 inhibitor: Stelara (ustekinumab); IL-23 inhibitors: Skyrizi (risankizumab-rzaa), Tremfya (guselkumab), and Ilumya (tildrakizumab-asmn); IL-17

IL-23 inhibitors such as Guselkumab, Tildrakizumab, and IL-12/-23 inhibitor Ustekinumab are a relatively newer class of drugs that have shown effectiveness in treating PsA. IL-23 and IL-17 inhibitors show similar efficacy at 1 year and over, however, when it comes to rapid response rate, IL-17 inhibitors are superior.

Both IL-23 and IL-17 inhibitors are effective in treating psoriasis. However, IL-23 is a more advanced concept than IL-17. IL-23 is an important

Risankizumab (Skyrizi), a subcutaneous IL-23 inhibitor, is indicated Guselkumab (Tremfya), another IL-23 inhibitor, is currently

(IL-17RA), Skyrizi (IL-23 inhibitor), Stelara (IL-12/23 inhibitor), Taltz agent Taltz; for pJIA, added criteria requiring use of preferred agents.

drugs called interleukin-23 (IL-23) inhibitors. Biologics are protein-based medications that target specific parts of the immune system. IL-23

Each diagnosis was confirmed by prescriptions of either IL-23 inhibitors (risankizumab, tildrakizumab, guselkumab) or IL-12/23 inhibitors (